ICCC Q3 2020 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+25.3% YoY

Gross Profit

$2M46.3% margin

Operating Income

-$251,598-6.8% margin

Net Income

-$322,888-8.7% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+25.5%

Cash Flow

Operating Cash Flow

-$667,327

Free Cash Flow

-$2M

Stock-Based Comp.

$62,397

Balance Sheet

Total Assets

$40M

Total Liabilities

$12M

Stockholders' Equity

$28M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+25.3%
Gross Profit	$2M	$1M	+18.7%
Operating Income	-$251,598	-$429,816	+41.5%
Net Income	-$322,888	-$502,535	+35.7%